Nasus Pharma will hold its annual and special general meeting on October 8, 2026, with shareholders registered on September 14 eligible to vote. The meeting will cover auditor reappointment, director-related matters and incentive stock options, while shareholders holding at least 1% of voting rights may propose agenda items.

Key Highlights

  • Brightman Almagor Zohar & Co. is proposed for reappointment as Nasus Pharma’s independent auditor.
  • Shareholders holding at least 1% of voting rights may submit an additional agenda item by September 10.
  • The agenda includes ordinary shares reserved for incentive stock Options under the 2019 Incentive Option Plan.

Nasus Pharma Ltd (AMEX: NSRX) will hold its annual and special general meeting on October 8, 2026.

Nasus Pharma Sets Voting Agenda for October Meeting

The board unanimously recommends voting “FOR” each proposal submitted for Shareholder approval. Voting may be conducted in person or through a proxy, and holders of ordinary shares can revoke submitted voting instructions in line with the Israeli Companies Law 5759-1999. Shareholders holding at least 1% of the company’s outstanding voting rights may submit an additional agenda item by September 10, 2026, through the company’s Tel Aviv offices or by email to Oren Elmaliach. Shareholders signing and submitting a proxy card declare whether they are controlling shareholders or have a personal interest in agenda items requiring that disclosure under the applicable Israeli regulations. Ordinary shares held through a bank or broker require voting instructions if holders want those shares counted on the proposals.